Skip to main content
. 2026 Mar 27;18(7):1092. doi: 10.3390/cancers18071092
SoC Standard of care
ER Oestrogen receptor
PR Progesterone receptor
HER2 Human epidermal growth factor receptor 2
pCR Pathological complete response
TOP2A Topoisomerase II alpha
PTEN Phosphatase and TENsin Homologue
EGFR Epidermal Growth Factor Receptor
IGF1R Insulin-like Growth Factor 1 Receptor
mTOR Mammalian Target of Rapamycin
PNL Purely non-invasive lesions
CEIN Co-existing invasive cancer
DCIS Ductal carcinoma in situ
TMA Tissue microarray
TNBC Triple negative breast cancer
IHC Immunohistochemistry
N Patient number
n Event number
FFPE Formalin-fixed paraffin-embedded
H-score Histochemical score
AUC Area under the curve
DDRD DNA damage response deficiency
FA/BRCA Fanconi anaemia/BRCA
WSIs Whole-slide images
AI Artificial intelligence